UB Paderborn / Katalog / Suche / in CDI

Targeting HER2 expression in cancer: New drugs and new indications

Bosnian journal of basic medical sciences, 2021-02, Vol.21 (1), p.1-4

2021

Volltextzugriff (PDF)

Phase III, Open-Label, Randomized Study Comparing Concurrent Gemcitabine Plus Cisplatin and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Patients With Stage IIB to IVA Carcinoma of the Cervix

Journal of clinical oncology, 2011-05, Vol.29 (13), p.1678-1685

2011

Volltextzugriff (PDF)

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

The lancet oncology, 2013-02, Vol.14 (2), p.125-133

2013

Volltextzugriff (PDF)

Expenditures on Oncology Drugs and Cancer Mortality‐to‐Incidence Ratio in Central and Eastern Europe

The oncologist (Dayton, Ohio), 2019-01, Vol.24 (1), p.e30-e37

2019

Volltextzugriff (PDF)

Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement

The oncologist (Dayton, Ohio), 2016-10, Vol.21 (10), p.1183-1190

2016

Volltextzugriff (PDF)

Differences in Outcomes Between Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer Patients in Upper Middle-Income versus High-Income Countries: A Retrospective Study from 4 Oncology Centers

Medical science monitor, 2023-06, Vol.29, p.e940356-e940356

2023

Volltextzugriff (PDF)

Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer

British journal of cancer, 2016-01, Vol.114 (2), p.163-170

2016

Volltextzugriff (PDF)

The Oncology Association of Bosnia and Herzegovina's Recommendations for Fertility Preservation in Oncologic Patients

Bosnian journal of basic medical sciences, 2022-09, Vol.22 (5), p.646-650

2022

Volltextzugriff (PDF)

Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial

World journal of gastroenterology : WJG, 2010-07, Vol.16 (25), p.3133-3143

2010

Volltextzugriff (PDF)

Managing an oncology clinic during the COVID-19 pandemic—how we did it in Sarajevo?

Memo - Magazine of European medical oncology, 2020-09, Vol.13 (3), p.255-256

Beslija, Semir

2020

Volltextzugriff (PDF)

ASCO 2019—Personal highlights on adjuvant breast cancer: (neo-)adjuvant therapy of HER2-negative HR-positive BC

Memo - Magazine of European medical oncology, 2019-12, Vol.12 (4), p.305-307

Beslija, Semir

2019

Volltextzugriff (PDF)

Comparative analysis of the access to health-care services and breast cancer therapy in 10 Eastern European countries

SAGE open medicine, 2020, Vol.8, p.2050312120922029-2050312120922029

2020

Volltextzugriff (PDF)

A clinicopathologic study of invasive apocrine carcinoma of the breast: A single‐center experience

The breast journal, 2018-11, Vol.24 (6), p.1105-1108

2018

Volltextzugriff (PDF)

Colorectal Cancer Surgical Treatment, our Experience

Medical archives (Sarajevo, Bosnia and Herzegovina), 2019-12, Vol.73 (6), p.412-414

2019

Volltextzugriff (PDF)

2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina

Bosnian journal of basic medical sciences, 2021-04, Vol.21 (2), p.120-135

2021

Volltextzugriff (PDF)

Investigation of IVS14 + 1G > A polymorphism of DPYD gene in a group of Bosnian patients treated with 5-Fluorouracil and capecitabine

Bosnian journal of basic medical sciences, 2010-05, Vol.10 (2), p.133-139

2010

Volltextzugriff (PDF)

Efficacy comparison of pazopanib and trabectedin vs standard chemotherapy in second line treatment of patients with metastatic soft tissue sarcomas: Experience from countries with limited resources

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e23555-e23555

2018

Volltextzugriff (PDF)

Neoadjuvant trastuzumab + pertuzumab in HER2 positive breast cancer in a country with limited resources: Evaluation of complete pathological response in a real world practice

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e12661-e12661

2018

Volltextzugriff (PDF)

Statistical Modeling of Relations Between PET/CT Parameters and CEA in Recurrent and Metastatic Colorectal Cancer

Acta informatica medica, 2023-06, Vol.31 (2), p.115-120

2023

Volltextzugriff (PDF)

Letter to the Editor/Response

The breast journal, 2019-05, Vol.25 (3), p.569-569

2019

Volltextzugriff (PDF)

Long term efficacy of nilotinib as front- and second-line therapy in Bosnia and Herzegovina: Real life experience

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e18549-e18549

2017

Volltextzugriff (PDF)

A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries

European journal of cancer (1990), 2020-08, Vol.135, p.130-146

2020

Volltextzugriff (PDF)

Effects of adding taxane to anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer

Medicinski glasnik, 2019-02, Vol.16 (1), p.77-82

2019

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Targeting HER2 expression in cancer: New drugs and new indications

Phase III, Open-Label, Randomized Study Comparing Concurrent Gemcitabine Plus Cisplatin and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Patients With Stage IIB to IVA Carcinoma of the Cervix

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial

Expenditures on Oncology Drugs and Cancer Mortality‐to‐Incidence Ratio in Central and Eastern Europe

Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement

Differences in Outcomes Between Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer Patients in Upper Middle-Income versus High-Income Countries: A Retrospective Study from 4 Oncology Centers

Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer

The Oncology Association of Bosnia and Herzegovina's Recommendations for Fertility Preservation in Oncologic Patients

Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial

Managing an oncology clinic during the COVID-19 pandemic—how we did it in Sarajevo?

ASCO 2019—Personal highlights on adjuvant breast cancer: (neo-)adjuvant therapy of HER2-negative HR-positive BC

Comparative analysis of the access to health-care services and breast cancer therapy in 10 Eastern European countries

Gemcitabine, Epirubicin, and Paclitaxel Versus Fluorouracil, Epirubicin, and Cyclophosphamide As First-Line Chemotherapy in Metastatic Breast Cancer: A Central European Cooperative Oncology Group International, Multicenter, Prospective, Randomized Phase III Trial

A clinicopathologic study of invasive apocrine carcinoma of the breast: A single‐center experience

Colorectal Cancer Surgical Treatment, our Experience

2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina

Investigation of IVS14 + 1G > A polymorphism of DPYD gene in a group of Bosnian patients treated with 5-Fluorouracil and capecitabine

Efficacy comparison of pazopanib and trabectedin vs standard chemotherapy in second line treatment of patients with metastatic soft tissue sarcomas: Experience from countries with limited resources

Neoadjuvant trastuzumab + pertuzumab in HER2 positive breast cancer in a country with limited resources: Evaluation of complete pathological response in a real world practice

Statistical Modeling of Relations Between PET/CT Parameters and CEA in Recurrent and Metastatic Colorectal Cancer

Letter to the Editor/Response

Long term efficacy of nilotinib as front- and second-line therapy in Bosnia and Herzegovina: Real life experience

A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries

Effects of adding taxane to anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer

Suchergebnisse filtern